2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2659

Poor Correlation Between Vectra DA and DAS28 Scores in Patients with Rheumatoid Arthritis
Abstract Number: 2660

Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Abstract Number: 2661

Assessing Information Needs for Chronic Disease Management in Rheumatoid Arthritis
Abstract Number: 2662

Validation of the Quickdash in the Assessment of Rheumatoid Arthritis Disease Activity
Abstract Number: 2663

Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice and Its Association with Disease Activity
Abstract Number: 2664

Flares Occur Frequently in RA Patients Undergoing Arthroplasty
Abstract Number: 2665

Improved Flare/ Remission Pattern in Rheumatoid Arthritis over the Recent Decades
Abstract Number: 2666

Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Abstract Number: 2667

Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment
Abstract Number: 2668

Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate
Abstract Number: 2669

Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy
Abstract Number: 2670

Comparison of M-DAS and DAS28, Two Composite Scores for Prediction of Structural Damages in Rheumatoid Arthritis: Data from the Espoir Cohort
Abstract Number: 2671

Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis
Abstract Number: 2672

Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States
Abstract Number: 2673

Association Between Anxiety and Depression and Rheumatoid Disease Severity: Results from an Established Rheumatoid Arthritis Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].